Virus-Vaccine combo takes on Hard-to-Treat cancers
NCT ID NCT03647163
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This early-phase trial tests a cancer-killing virus (VSV-IFNβ-NIS) combined with immunotherapy drugs in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine carcinoma, and renal cell carcinoma. The virus is designed to infect and destroy cancer cells while also boosting the immune system. The study aims to find the safest and most effective dose and to see if the combination can shrink tumors. About 33 to 86 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oncolytic virus (VSV-IFNβ-NIS) combined with checkpoint inhibitors (pembrolizumab or ipilimumab + nivolumab)
What this could lead to
If successful, this could offer a new treatment option for patients with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants (up to 86). The virus and drug combination may cause side effects, and it is not yet known if it will effectively shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.